Want to see CVM full AI Analyst Report?
CVM Stock Chart & Stats
$1.48
$0.01(0.85%)
At close: 4:00 PM EDT
$1.48
$0.01(0.85%)
Day’s Range― - ―
52-Week Range$0.89 - $12.68
Previous Close$0.36
Volume124.96K
Average Volume (3M)125.69K
Market Cap
$28.14M
Enterprise Value$13.97
Total Cash (Recent Filing)$6.53M
Total Debt (Recent Filing)$7.89M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Dec 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.58
Shares Outstanding17,588,987
10 Day Avg. Volume66,836
30 Day Avg. Volume125,686
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.16
Revenue Forecast (FY)$4.69M
Bulls Say, Bears Say
Bulls Say
CDMO Revenue DiversificationThe CDMO operation provides a potential recurring-service revenue stream that is less dependent on successful drug approval. It also uses existing biologics manufacturing capabilities to diversify the business beyond the investigational Multikine program.
Clinical Pipeline OptionalityMultikine gives Cel-Sci a defined clinical asset and potential product-commercialization pathway. If development and regulatory objectives are achieved, an approved therapy could materially expand revenue beyond the company’s current service-based opportunities.
Historically Moderate LeverageThe historical balance sheet indicates that Cel-Sci operated with moderate leverage and a positive equity base, providing some evidence of prior financial flexibility. This is a limited strength because the latest period shows significant balance-sheet volatility.
Bears Say
No Demonstrated Revenue BaseZero reported revenue confirms that Cel-Sci remains pre-commercial, leaving its operating model dependent on funding, development progress, and potential future CDMO contracts. Profitability and commercial scalability therefore remain unproven over the medium term.
Persistent Cash BurnConsistently negative operating and free cash flow means the business is not self-funding. Continued clinical development and operations will likely require additional financing or monetization, creating dilution, liquidity, and execution risk.
Balance-Sheet VolatilityThe sharp TTM increase in reported debt, assets, and equity is a major departure from historical levels and creates substantial uncertainty about financial quality. Even with a manageable reported debt-to-equity ratio, the volatility complicates capital planning and risk assessment.
Cel-Sci News
CVM FAQ
What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was $0.89 and its highest was $12.68 in the past 12 months.
What is Cel-Sci Corp.’s market cap?
Cel-Sci Corp.’s market cap is $28.14M.
When is Cel-Sci Corp.’s upcoming earnings report date?
Cel-Sci Corp.’s upcoming earnings report date is Dec 23, 2026 which is in 116 days.
How were Cel-Sci Corp.’s earnings last quarter?
Cel-Sci Corp. released its earnings results on Aug 17, 2026. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Cel-Sci Corp. overvalued?
According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued.
Does Cel-Sci Corp. pay dividends?
Cel-Sci Corp. does not currently pay dividends.
What is Cel-Sci Corp.’s EPS estimate?
Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-Sci Corp. have?
Cel-Sci Corp. has 17,588,987 shares outstanding.
What happened to Cel-Sci Corp.’s price movement after its last earnings report?
Cel-Sci Corp. reported an EPS of -$0.47 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.649%.
Which hedge fund is a major shareholder of Cel-Sci Corp.?
Currently, no hedge funds are holding shares in CVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cel-Sci Corp.
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Technical Analysis
Ownership Overview
4.14% Insiders
1.83% Mutual Funds
0.11% Other Institutional Investors
90.80% Public Companies and
Individual Investors